0
0
NEW DELHI — India’s top drug regulatory body, the Central Drugs Standard Control Organisation (CDSCO), has flagged more than 50 batches of medicines as “Not of Standard Quality” (NSQ) in its latest monthly surveillance report. The state-monitored alert includes highly common, everyday medications such as paracetamol (used for pain and fever), telmisartan (used for high blood pressure), calcium and vitamin D3 supplements, anti-diabetes pills, and the popular antacid combination Pan D. The announcement highlights the ongoing efforts of India’s post-market surveillance system to detect manufacturing anomalies early, though it also raises vital questions about quality consistency across the country’s vast pharmaceutical supply chain.
Understanding the Alert: NSQ vs. Spurious Drugs
The CDSCO publishes monthly alerts to notify manufacturers, healthcare professionals, and consumers about specific drug batches that fail laboratory testing. In this latest round, samples failed critical benchmarks outlined in the Indian Pharmacopoeia—the official book of standards for drugs manufactured and marketed in India. The specific failures included issues with dissolution (how well the pill dissolves in the body), assay (the actual strength and purity of the active ingredient), water content, and uniformity of weight.
It is crucial for the public to understand the regulatory distinction between a routine quality failure and a counterfeit product.
According to official CDSCO guidelines under the Drugs and Cosmetics Act of 1940, “spurious” drugs are those that are deliberately and fraudulently mislabeled, substituted, or counterfeited to imitate another product. The vast majority of the drugs flagged in this month’s alert are categorized as NSQ, meaning they are genuine products manufactured by licensed companies that simply fell short of one or more technical quality metrics during routine testing.
The Scope of the Problem and Past Patterns
This latest report is not an isolated incident but part of a routine, robust monthly enforcement process. However, health advocates note that the recurring appearance of essential, mass-market medicines points to a broader systemic challenge.
In similar CDSCO reports published in recent years, including an extensive list flagged early last year, paracetamol and cardiovascular drugs like telmisartan have repeatedly appeared on NSQ lists. Because these specific therapeutic categories represent millions of daily prescriptions across India, even a minor percentage of substandard batches can theoretically expose a significant number of patients to unpredictable clinical outcomes.
Why Quality Failures Matter to Patient Care
When a medicine is designated as substandard, it does not automatically mean the drug is toxic or inherently dangerous. Instead, the primary medical concern is clinical efficacy—whether the drug will actually work the way it is supposed to.
-
Under-dosing and Treatment Failure: If an anti-diabetes pill or a blood pressure medication like telmisartan fails its assay test and contains less active ingredient than stated, a patient’s blood sugar or blood pressure could remain dangerously unmanaged.
-
Dissolution Blockages: If a paracetamol tablet fails its dissolution test, it may pass through the patient’s digestive system without fully releasing the medication, leaving them in pain or failing to break a high fever.
-
Storage Vulnerabilities: Some failures occur not at the factory, but due to improper storage conditions, such as exposing moisture-sensitive pills to high humidity, causing them to degrade prematurely.
Expert Perspectives: Caution Without Panic
Independent healthcare experts urge the public to approach these regulatory alerts with a balanced mindset.
“An NSQ alert is evidence that our safety checks are working, not a reason to panic,” says Dr. Sanjay Verma, an independent clinical pharmacologist and public health consultant not involved with the CDSCO report. “When a batch is flagged, the regulator initiates a recall of that specific batch. It absolutely does not mean that every single strip of paracetamol or telmisartan on pharmacy shelves is compromised. Patients should look at these reports calmly but carefully.”
Dr. Verma stresses that the public-health infrastructure relies heavily on these transparent notices to prompt hospitals and pharmacies to clear substandard stock before it reaches the patient.
Practical Guidance for Consumers and Healthcare Providers
For health-conscious consumers and medical professionals, navigating these alerts requires a systematic approach. If you or a family member takes any of the medications listed in the latest alert, follow these clear safety steps:
1. Verify the Batch Number
Do not rely on the brand name alone. Look at the back of your medicine strip, bottle, or carton to locate the specific Batch Number (often abbreviated as B.No. or Batch). Compare it directly with the official NSQ list published on the CDSCO portal.
2. Do Not Abruptly Stop Medication
If your medicine’s batch number matches an entry on the flagged list, do not stop taking it immediately on your own. This is especially critical for maintenance therapies like blood pressure or anti-diabetes medications. Suddenly stopping blood pressure drugs can trigger dangerous, sudden spikes in hypertension. Instead, take the packet to your local pharmacist or treating physician to arrange for a safe replacement from a compliant batch.
3. Role of Pharmacists and Hospitals
For pharmacists, procurement teams, and clinicians, these monthly updates serve as an immediate directive to audit existing inventory. Hospitals and clinics are advised to track treatment failures or unusual patient complaints—such as a blood pressure regimen suddenly losing efficacy—as these can be early indicators of a substandard batch in circulation.
Limitations of the Surveillance Data
While the CDSCO portal provides an essential public service, medical policy experts point out its intrinsic limitations. A batch listed as NSQ confirms a quality failure, but the public data alone does not pinpoint the root cause of the failure. It does not explicitly state whether the defect stemmed from a manufacturing error, poor raw materials, inadequate transport conditions in high heat, or localized pharmacy storage issues. Finding these answers requires subsequent, deeper investigations by state and central drug inspectors, meaning that definitive blame cannot be assigned to manufacturers based on the initial alert alone.
Nevertheless, the continuing recurrence of quality alerts for foundational medicines underscores the vital necessity of rigorous, unyielding post-market surveillance to protect patient health nationwide.
References
-
The Hindu: “Over 50 drugs, including paracetamol, ‘not of standard quality’, says CDSCO report,” Published September 25, 2024.
Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
